Compared to other treatments for mCRPC, such as chemotherapy (e.g., docetaxel) and newer hormonal therapies (e.g., abiraterone, enzalutamide), Provenge offers a unique approach by harnessing the patient's immune system. While chemotherapy and hormonal therapies target cancer cells directly, Provenge works by enhancing the patient's immune response. This can be beneficial for patients who are not candidates for chemotherapy or who prefer a treatment with a different side effect profile.